Marston to Lead SonoPrep(R) Product Launch
FRANKLIN, Mass., June 1 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq SC: SONT) announced today that Barry D. Marston has joined
the Company as Vice President of Sales and Marketing. In this new position,
Mr. Marston will be responsible for commercializing Sontra's transdermal drug
delivery and diagnostic products including Sontra's ultrasonic SonoPrep skin
permeation device and topical lidocaine kit for rapid skin anesthesia which is
expected to be launched in the third quarter 2004, pending FDA 510(k)
marketing clearance.
Mr. Marston has over eighteen years of sales, marketing and business
development experience in the medical device industry and has a proven track
record of successfully introducing new medical technologies and expanding
sales. Most recently, Mr. Marston was Director of Marketing and Business
Development at Lifecore Biomedical. Prior to that role, Mr. Marston obtained
diverse medical device experience working in senior management positions for
Boston Scientific, Medex, Ethicon Endo-Surgery and UltraCision.
"We are delighted to have Barry Marston join Sontra to head up sales and
marketing as we prepare to launch our first product," stated Thomas W.
Davison, PhD, Sontra's President and Chief Executive Officer. "Barry is a very
energetic and innovative leader who possesses strong industry knowledge and
contacts, particularly in the intravenous therapy market which will help
facilitate the commercial launch of our SonoPrep device and topical lidocaine
kit."
In February 2004, the FDA granted Sontra its first 510(k) marketing
clearance for SonoPrep for use in electrophysiology applications and in March
2004 the Company submitted a 510(k) application seeking marketing clearance
for the use of SonoPrep and a topical lidocaine procedure tray to achieve
rapid skin anesthesia. This 510(k) application was supported by clinical data
from three studies covering 500 patients that demonstrated rapid skin
anesthesia with 4% lidocaine was achieved within five minutes following a skin
pre-treatment with SonoPrep. Existing topical lidocaine products addressing
this $100 million market require a thirty to sixty minute waiting period
before skin anesthesia is achieved.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a leading developer of transdermal drug
delivery and diagnostic products that combine Sontra's SonoPrep ultrasound-
mediated skin permeation technology with synergistic biosensor and transdermal
drug delivery technologies. Sontra's products under development include:
SonoPrep and a topical anesthetic kit for rapid (within five minutes) skin
anesthesia; a continuous non-invasive glucose monitor developed in
collaboration with Bayer Diagnostics and the use of SonoPrep for the
transdermal delivery of vaccines and large molecule drugs.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected timing of the
commercial availability of the SonoPrep device and lidocaine procedure tray.
Statements that are not historical facts, including statements about our
beliefs and expectations, are forward-looking statements. Such statements are
based on our current expectations and are subject to a number of factors and
uncertainties, which could cause actual results to differ materially from
those described in the forward-looking statements. The following important
factors and uncertainties, among others, could cause actual results to differ
materially from those described in these forward-looking statements: adverse
results in product development, clinical trials and commercialization efforts;
difficulties or delays in obtaining regulatory approvals to market products
resulting from development efforts; failure to obtain and maintain patent
protection for discoveries; commercial limitations imposed by patents owned or
controlled by third parties; dependence upon strategic partners to develop and
commercialize products based on our work; the commercial success of products;
and the requirement for substantial funding to conduct research and
development and to expand commercialization activities. For detailed
information about factors that could cause actual results to differ materially
from those described in the forward-looking statements, please refer to
Sontra's filings with the Securities and Exchange Commission, including
Sontra's most recent Quarterly Report on Form 10-QSB. Forward-looking
statements represent management's current expectations and are inherently
uncertain. We do not undertake any obligation to update forward-looking
statements made by us.
Contact:
Sean Moran, CFO
Sontra Medical Corporation
Tel: 508-553-8850
Evan Smith, CFA/Erica Pettit
KCSA Worldwide
Tel: 212-896-1248 / 212-896-1289
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Sean Moran, CFO of Sontra Medical
Corporation, +1-508-553-8850; or Evan Smith, CFA,
+1-212-896-1248, or Erica Pettit, +1-212-896-1289, both of KCSA
Worldwide
|
